Table 2.
Unadjusted Primary and Secondary Outcomes
| Outcome | Patients, No. (%) | ||||
|---|---|---|---|---|---|
| FQ (n = 289) | TMP-SMX (n = 73) | HBBL (n = 214) | IVBL (n = 108) | LBBL (n = 75) | |
| Primary outcomes | |||||
| Recurrence within 60 d | 21 (7.3) | 7 (9.6) | 46 (21.5) | 22 (20.4) | 15 (20.0) |
| Recurrent bacteremia + UTI | 3 (1.0) | 1 (1.4) | 9 (4.2) | 5 (4.6) | 2 (2.7) |
| Recurrent UTI only | 18 (6.2) | 6 (8.2) | 37 (17.3) | 17 (15.7) | 13 (17.3) |
| Secondary outcomes | |||||
| Recurrence within 30 d | 12 (4.2) | 4 (5.5) | 31 (14.5) | 15 (13.9) | 10 (13.3) |
| Recurrence within 90 d | 26 (9.0) | 11 (15.1) | 56 (26.2) | 32 (29.6) | 17 (22.7) |
| UTI-related readmission within 90 d | 28 (9.7) | 11 (15.1) | 46 (21.5) | 35 (32.4) | 13 (17.3) |
| Clostridioides difficile infection within 90 d | 0 (0.0) | 1 (1.4) | 3 (1.4) | 4 (3.7) | 1 (1.3) |
| All-cause 90-d mortality rate | 3 (1.0) | 1 (1.4) | 5 (2.3) | 2 (1.9) | 2 (2.7) |
Abbreviations: FQ, fluoroquinolone; HBBL, high-bioavailability β-lactam; IVBL, intravenous β-lactam; LBBL, low-bioavailability β-lactam; TMP-SMX, trimethoprim-sulfamethoxazole; UTI, urinary tract infection.